Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minLeaning Bullish
5 minSymmetric Triangle
Daily trend turns up above $5.46
Key levels
Resistance$4.90
Resistance$4.47
Support$3.92
Support$3.46
Latest news & SEC filings
EarningsTaysha Gene Therapies holds Q3 2026 earnings call
EarningsTaysha Gene Therapies Posts Q3 2026 Financials
SEC FilingTaysha Gene Therapies, Inc. filed a report on a major company event (Form 8-K)
EarningsTaysha Gene Therapies posts smaller quarterly loss than expected
All TSHA news →Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing gene therapies for severe neurological diseases. Its lead product candidate, TSHA-102, targets Rett syndrome, and the company also pursues other programs for central nervous system disorders. The company serves patients with rare genetic conditions and operates primarily in the United States.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
SEPT Low Target
$10.00
SEPT Mid Target
$13.50
SEPT High Target
$17.00
Analyst Consensus
$13.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TSHA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$10.80
23
Moat Score
NONE
4/9
Piotroski Score
5.6
Altman Z-Score
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Long Alison S | director | Buy | 21,335 | - | Jun 1, 2026 |
| Sepp-Lorenzino Laura | director | Buy | 21,335 | - | Jun 1, 2026 |
| Stalfort John A III | director | Buy | 21,335 | - | Jun 1, 2026 |
| Donenberg Phillip B. | director | Buy | 21,335 | - | Jun 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
17.3%
3yr Revenue CAGR
57.5%
EPS Growth YoY
5.56%
FCF Growth YoY
-15.0%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for TSHA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:11 | $4.21 | 2,714 | $$11K | MIDPOINT |
| 21:00:11 | $4.21 | 12,189 | $$51K | MIDPOINT |
| 21:00:11 | $4.21 | 2,434 | $$10K | MIDPOINT |
| 21:00:11 | $4.21 | 2,244 | $$9K | MIDPOINT |
| 20:59:58 | $4.21 | 1,000 | $$4K | SELL |
5 dark pool trades shown · $$87K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Taysha Gene Therapies, Inc. (TSHA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Taysha Gene Therapies, Inc. (TSHA) is at $4.21, down 1.64% (-$0.07) at the Nov 12, 2026 close.
Latest TSHA news — Nov 12, 2026: Taysha Gene Therapies holds Q3 2026 earnings call · Nov 12, 2026: Taysha Gene Therapies Posts Q3 2026 Financials
The average analyst price target for TSHA is $13.50, ranging from $10 to $17, based on 6 analysts. Latest: Goldman Sachs maintains on Jul 21, 2026.
Analyst ratings for TSHA: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
TSHA last reported on Aug 11, 2026: EPS -$0.13 vs -$0.11 expected — a miss of 14.7%.
TSHA does not currently pay a dividend.
Support: $3.92, $3.46. Resistance: $4.47, $4.90, $5.46.
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
Nov 12, 2026: Taysha Gene Therapies holds Q3 2026 earnings call · Nov 12, 2026: Taysha Gene Therapies Posts Q3 2026 Financials · Nov 12, 2026: Taysha Gene Therapies, Inc. filed a report on a major company event (Form 8-K)